Optical biomarker detection
Platform direction for optical detection of selected biomarker signals.
PRAM
Photonic Resonator Absorption Microscopy.
PRAM is GNGBM's patented-platform-based approach for ultra-sensitive biomarker detection. The platform is being developed for diagnostic applications in oncology and infectious disease, with a focus on affordability, scalability and decentralized use.
Applications
Digital signal counting
Development focus on countable signal events for sensitive analytical workflows.
Amplification-free analysis
Designed around workflows that reduce reliance on amplification-dependent analysis.
Oncology applications
Research direction for cancer-associated biomarkers and liquid-biopsy use cases.
Infectious-disease applications
Development direction for selected pathogen, antigen and host-response targets.
Domestic manufacturing direction
Aligned with scalable, accessible and India-focused diagnostic deployment.
Target Biomarker Classes
Focused categories for development, not a proprietary target list.
Oncology targets
Circulating tumour DNA, cell-free nucleic acids, miRNA, exosomal targets, protein biomarkers and selected cancer-associated molecular markers.
Infectious-disease targets
Pathogen nucleic acids, microbial antigens, host-response markers, syndrome-associated molecular targets and selected priority pathogens relevant to Indian clinical needs.
Development directions
Application areas are organized around clinical relevance, decentralized access and commercially practical assay translation.
PRAM development
Cancer diagnostics development
- Liquid-biopsy research
- Early detection research
- Therapy monitoring
- Residual-disease research
- Recurrence surveillance
- Biomarker detection
Infectious-disease development
- Multiplex assay development
- Syndromic testing
- Priority pathogen research
- Decentralized laboratory use
- Portable testing direction
- Commercial assay translation planning
Development status
GNGBM platforms and assays described on this website are under development. Product availability, intended use and regulatory status may vary and will be communicated following applicable evaluation and approvals.
Supported by a patented technology: US Patent No. 11,041,187 B2; US Patent No. 7,768,640 B2